Organization
MaaT Pharma
4 clinical trials
38 abstracts
Clinical trial
Safety, Tolerability and Gut microbIota AnalysiS of an Oral Microbiotherapy in Amyotrophic Lateral Sclerosis; an Open-label Phase 1b Pilot TrialStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Evaluation of the Efficacy of MaaT013 as Salvage Therapy in Acute GVHD Patients With Gastrointestinal Involvement, Refractory to Ruxolitinib; a Multi-center Open-label Phase III Trial.Status: Recruiting, Estimated PCD: 2023-09-30
Clinical trial
A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)Status: Recruiting, Estimated PCD: 2026-10-31
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
National survey of patient perspectives on medication costs among co-pay assistance recipients with cancer.Org: University of Oklahoma Health Sciences Center, Oklahoma City, Okyo Pharma, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
Association between comorbidity clusters and mortality in patients with cancer: A machine learning analysis of data from the US National Health and Nutrition Examination Survey 1999–2018.Org: School of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Sanatorium & Hospital, China National Biotec Group,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.Org: Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, Women and Infants Hospital of Rhode Island, University of Illinois at Chicago,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.Org: Ontario Institute for Cancer Research, Toronto, ON, Canada, MASS General Hospital BHX-1, Mayo Clinic Department of Oncology, Progendis, Caris Life Sciences,
Abstract
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).Org: Cancer Center, Stanford, Palo Alto, CA, Foundation Medicine, Inc., San Diego, CA, Foundation Medicine, Inc., Cambridge, MA, SUNY Upstate Medical University, Syracuse, NY, Foundation Medicine, Inc., Boston, MA,
Abstract
Unstructured EMR data hold the key to oncology studies: Methods for validating NLP-extracted phenotypes from EMR notes.Org: IQVIA, Boston Pharmaceuticals, MaaT Pharma, South Bend, Intercept Pharmaceuticals,
Abstract
Characterization of the BCMA epitope bound by BCMA-CD3 T cell engager elranatamab.Org: Pfizer Inc., San Diego State University Department of Biology, San Diego, CA, CanSino Biologics, Cambridge University Hospitals NHS Foundation Trust, MaaT Pharma,
Abstract
Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Org: Precede Biosciences, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
Impact of hyponatremia on multiple myeloma hospitalizations: A nationwide analysis.Org: Brooklyn Hospital Center, Brooklyn, NY, Brooklyn ImmunoTherapeutics, Nykode Therapeutics, The Brooklyn Hospital Center, New York, NY, New York Oncology Hematology PC,
Abstract
Dual targeting of αv and α5β1 integrins in triple-negative breast cancer (TNBC).Org: Tufts Medical Center/Tufts University, Boston Pharmaceuticals, MaaT Pharma, Tufts University School of Medicine,
Abstract
Dedifferentiated chordoma: Socioeconomic factors and treatment outcomes.Org: Brandeis University, Waltham, MA, MaaT Pharma, Creighton University School of Medicine Phoenix Regional Campus, Omaha NE,
Abstract
Epidemiological trends and socioeconomic factors in malignant peripheral nerve sheath tumors with rhabdomyoblastic differentiation: A National Cancer Database study.Org: Creighton University School of Medicine-Phoenix, Phoenix Tissue Repair, Azidus Brasil, Creighton SOM, Brandeis University,
Abstract
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Org: School of Medicine, Zhejiang University, Hangzhou, China, Yale University, New Haven, CTI BioPharma, Keck School of Medicine of the University of Southern California,
Abstract
Aggregated analysis of 1,000 patients with cancer to assess the benefits of integrated whole exome and whole transcriptome sequencing.Org: BostonGene Corporation, Waltham, MA, MaaT Pharma, Corp.,
Abstract
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).Org: Medical Oncology Group, Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA,
Abstract
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Massachusetts General Hospital, Boston Pharmaceuticals,
Abstract
AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors.Org: Affini-T Therapeutics, Inc., Watertown, NY, MaaT Pharma, Seattle Gummy Company, Wave Life Sciences,
Abstract
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.Org: Massachusetts General Hospital, Harvard Medical School, Oryzon Genomics, Cornella De Llobregat, Barcelona Clinic Liver Cancer,
Abstract
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.Org: Mayo Clinic, Rochester Regional Health System, MN, Mayo Clinic College of Medicine, Takeda Development Center Americas, Inc., Lexington, MA, USA,
Abstract
The impact of portability of wearable monitoring device on study retention and participant experience in patients with unresectable stage III NSCLC treated with standard-of-care durvalumab: Learnings from the ON TRAX pilot study.Org: AstraZeneca, Gaithersburg, MD, MD Anderson Cancer Center, Current Health, Boston Pharmaceuticals,
Abstract
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,
Abstract
Outcomes of patients with advanced NF1-mutant melanoma treated with MEK inhibitors.Org: California Pacific Medical Center Research Institute, San Francisco, CA, San Francisco Department of Public Health, CanSino Biologics, Stockton Hematology/Oncology, Lodi,
Abstract
Real-world treatment patterns of non-small cell lung cancer in an Indian hospital.Org: Mango Sciences, Inc., Boston Pharmaceuticals, MaaT Pharma, Subhash Nagar, Nelamangala,
Abstract
In-hospital outcomes of patients with breast cancer and venous thromboembolism.Org: St Vincent Hospital, Worcester HIV Vaccine, MaaT Pharma, Brooklyn Hospital Program, Brooklyn ImmunoTherapeutics,
Abstract
Recurrent versus non-recurrent triple negative breast cancer: An institutional study.Org: Geisinger Northeast, Wilkes Barre, PainReform, The Pennsylvania State University, State College,
Abstract
Treatment patterns and outcomes among locally advanced cervical cancer patients receiving concurrent chemoradiotherapy.Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, MaaT Pharma, Merck & Co., Inc., Rahway, NJ,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
Phase 1/2 study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors.Org: Allorion Therapeutics, Natick, MA, MaaT Pharma,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,
Abstract
Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis.Org: Federal University of Pará - UFPA, Belem, Brazil, Princess Margaret Hospital, Toronto Allergy and Asthma Centre,
Abstract
Trends and factors related to pregnancy after breast cancer treatment in young patients.Org: Asan Medical Center, Seoul National University Hospital, South Korea, Seoul St. Mary's Hospital, Korea, Republic of (South),
Abstract
BIOCOMPATIBILITY AND PERSISTENCE OF COMPONENTS OF HYLASTAN SGL-80, A NON-AVIAN HA VISCOSUPPLEMENT, IN A GUINEA PIG INTRA-ARTICULAR INJECTION MODEL Org: Drug and Biomaterial R&D, Genzyme, Framingham, MaaT Pharma, Manufacturing Technical Support,